Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors

NCT06380660 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

298

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor, Adult
BRCA1 Mutation
BRCA2 Mutation
Ovarian Cancer
Breast Cancer
Prostate Cancer

Interventions

DRUG: ACE-86225106 tablet

Sponsor

Acerand Therapeutics (Shanghai) Limited